A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- NCT ID
- NCT06473597
- Registry status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Antonios Likourezos
- Conditions
- Migraine
Overview
ClinicalTrials.gov lists this study as Recruiting.
Official title: A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial
Enrollment: 80 participants (Estimated).
What is being studied
- Drug: Rimegepant
- Intervention: rimegepant sulfate
- Intervention: rizatriptan
- Drug: Rizatriptan Benzoate
Who may be eligible
- Ages
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers accepted
- No
ClinicalTrials.gov lists the following eligibility criteria.
Study locations
1 study location is listed.
Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.
Countries: United States
- New York, United States: 1
Sample of listed locations
- Maimonides Medical Center — Brooklyn, New York, 11219, United States — Recruiting
Study details
- Start date
- September 1, 2024
- Primary completion date
- December 31, 2028
- Completion date
- December 31, 2028
- First posted
- June 25, 2024
Source and update information
- Source
- ClinicalTrials.gov
- NCT ID
- NCT06473597
- Registry last updated
- September 24, 2026
- QualifiedStudies registry data refreshed
- October 5, 2026
- QualifiedStudies record fetched
- October 5, 2026
View NCT06473597 on ClinicalTrials.gov
Trial information can change. Confirm current study details with the study team or the registry.
About joining clinical research
Find clinical trials you may match with
QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.
Find clinical trials you may match with | Migraines studies | Clinical trial FAQ